In this episode,Charles talks with Amber Tong, a senior editor at Endpoints News, about how the Biosecure Act could impact the biotech and pharma sectors.

Amber shares thoughts on how this law could change U.S.-China biopharma ties, jobs, and making medicines. We also look into how things are changing in this area, who might benefit or not, and the big global tensions that affect these shifts.

Here's what you are in for:

00:00 Introduction

00:33 Welcoming the Guest

02:36 Discussing the Biosecure Act

04:34 Impact on the Biotech Industry

07:17 Geopolitical Tensions and Historical Context

16:09 Potential Winners and Losers

35:16 Future Predictions and Conclusion

About Amber Tong

Amber Tong is a senior editor at Endpoints News, which is a global specialty publication covering the biotech and pharmaceutical industries. She's a reporter/editor with more than six years of experience covering the biopharma industry, with a particular focus on the growing role China plays on the global stage.

Amber is also at BIO San Diego 2024, go say hi.

Useful Information on BIOSECURE

Endpoints' latest articles:

BIO: China tensions, fixing gene therapy’s business model, and the stop-start market recovery

https://endpts.com/see-you-at-bio-china-tensions-fixing-gene-therapys-business-model-and-the-stop-start-market-recovery/

WuXi became a critical partner to biopharma companies. They’re not ready if the US cracks down

https://endpts.com/wuxi-became-a-critical-partner-to-biopharma-companies-theyre-not-ready-if-the-us-cracks-down/

The US could upend biopharma manufacturing. WuXi rivals have an opening

https://endpts.com/the-us-could-upend-biopharma-manufacturing-wuxi-rivals-have-an-opening/

US-China tensions threaten to ensnare additional Chinese biopharma contractors

https://endpts.com/us-china-tensions-threaten-to-ensnare-additional-chinese-biopharma-contractors/

New Biosecure draft features 2032 grandfather clause, five-year grace period for added companies

https://endpts.com/new-biosecure-draft-features-2032-grandfather-clause-five-year-grace-period-for-added-companies/

BIO CEO defends the organization's about-face on the Biosecure Act

https://endpts.com/bio-ceo-defends-the-organizations-about-face-on-the-biosecure-act/

Medicxi backs Chinese biotech's next-gen KRAS G12C drug with $40M injection

https://endpts.com/medicxi-backs-d3-bios-next-gen-kras-g12c-drug-with-40m-injection/

About Charles

Charles Spence...

In this episode, Charles talks about his top rules for success in recruiting, which he calls 'The 10 Commandments of Recruitment.' He believes that having principles or commandments as a person or business is what sets us apart.

He also shares a bit of fun insight about who he is and what he believes in business.

Here's what you are in for:

00:08 The 10 Commandments of Recruitment

00:14 Commandment 1: Always Give Feedback

00:47 Commandment 2: Don't Add to the Problem

02:47 Commandment 3: It's Not Personal

03:20 Commandment 4: Pride in Work Before Business

04:18 Commandment 5: Always Be Learning

05:07 Commandment 6: Understand Before Advising

06:04 Commandment 7: Don't Be an Idiot

06:15 Commandment 8: Be Refreshingly Honest

07:01 Commandment 9: Be Authentic

08:00 Commandment 10: Be Different and Keep Going

About Charles

Charles Spence leads Discera, a leading recruitment firm specializing in the biopharma industry.

He graduated with a biomedical degree, has worked in hospitals (including translation work in Seoul, South Korea), and also spent years doing diabetes research. After doing research and travel, a career in business and science felt the most appropriate.

In 2023, Charles decided to launch his firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH.

Connect with Charles:

LinkedIn: https://www.linkedin.com/in/charles-spence-clinical/

Website: https://www.discera-search.com/

In this episode, Colin Hayward, CMO of Telix- a commercial-stage biopharmaceutical company, talks about his contribution to the success of Rituximab which culminated in transforming it into a $3 billion radiopharmaceutical giant.

He also shares invaluable insights into the challenges of leadership, the burden of firing people, and the strategic decisions that drive success in the fast-paced world of biotech innovation.

Here's what you are in for:

01:36 Colin's Switch from Medicine to Biotech

04:15 Moving from Treating Patients to Business

05:58 Lessons from Working on Rituxan

10:59 Changing Careers: Consulting, CROs, and Teamwork

23:03 Tips on Hiring and Making a Strong Biotech Team

27:45 The burden of Firing people

About Colin Hayward

Colin Hayward, MD is the former Chief Medical Officer at Telix Pharmaceuticals, a company that specializes in radiopharmaceuticals. He has over 20 years of experience in the global pharmaceutical and biotech industries. Colin leads the medical, regulatory, clinical operations, and safety activities at Telix worldwide.

He originally wanted to play football professionally for Brighton Hove Albion, but realized he wasn't good enough at age 12. Switched to field hockey, was academically gifted, loved science, and decided to pursue medicine to help people and dive deeper into science.

About Charles

Charles Spence leads Discera, a leading recruitment firm specializing in the biopharma industry.

He graduated with a biomedical degree, has worked in hospitals (including translation work in Seoul, South Korea), and also spent years doing diabetes research. After doing research and travel, a career in business and science felt the most appropriate.

In 2023, Charles decided to launch his firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH.

Connect with Charles:

LinkedIn: https://www.linkedin.com/in/charles-spence-clinical/

Website: https://www.discera-search.com/